Fluconazole

Fluconazole

SCHEMBL3151

OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ERG11

The experimentally established mechanism targets of Fluconazole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 16/20 1.00
CYP2C9 P11712 12/20 1.00
CYP2C19 P33261 12/20 1.00
LMNA P02545 2/20 1.00
HSP90AA1 P07900 1/20 1.00
CYP19A1 P11511 1/20 1.00
CYP11B1 P15538 1/20 1.00
CYP11B2 P19099 1/20 1.00
ADRA1A P35348 1/20 1.00
CYP51A1 Q16850 1/20 1.00
CYP2B6 P20813 1/20 0.58
CYP3A5 P20815 1/20 0.58
CYP3A7 P24462 1/20 0.58
MAPK1 P28482 1/20 0.58
CYP3A43 Q9HB55 1/20 0.58
CYP46A1 Q9Y6A2 1/20 0.58
CYP1A2 P05177 6/20 0.53
CYP2D6 P10635 6/20 0.53
KMT2A Q03164 1/20 0.51
HDAC3 O15379 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Fluconazole SCHEMBL29360276 1.00 CYP3A4 (1.00) CYP3A4CYP2C9CYP2C19LMNAHSP90AA1
Fluconazole SCHEMBL5503188 1.00 CYP3A4 (1.00) CYP3A4CYP2C9CYP2C19LMNAHSP90AA1
Fluconazole SCHEMBL5597261 1.00 CYP3A4 (1.00) CYP3A4CYP2C9CYP2C19LMNAHSP90AA1
Fluconazole SCHEMBL27971366 0.99 CYP3A4 (0.97) CYP3A4CYP2C9CYP2C19LMNAHSP90AA1
Fluconazole SCHEMBL20305060 0.99 CYP3A4 (0.97) CYP3A4CYP2C9CYP2C19LMNAHSP90AA1
Fluconazole SCHEMBL28141272 0.99 CYP3A4 (0.97) CYP3A4CYP2C9CYP2C19LMNAHSP90AA1
Fluconazole SCHEMBL27534402 0.99 CYP3A4 (0.97) CYP3A4CYP2C9CYP2C19LMNAHSP90AA1
Fluconazole SCHEMBL27971503 0.99 CYP3A4 (0.97) CYP3A4CYP2C9CYP2C19LMNAHSP90AA1
Fluconazole SCHEMBL2244102 0.99 CYP3A4 (0.97) CYP3A4CYP2C9CYP2C19LMNAHSP90AA1
Fluconazole SCHEMBL27514614 0.99 CYP3A4 (0.97) CYP3A4CYP2C9CYP2C19LMNAHSP90AA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 63998 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4747280-A2 METHODS FOR TREATING MULTIPLE MYELOMA Janssen Biotech, Inc. (US) 2026-05-27 EP claimed
CN-122094963-A Cardioprotective lipids and methods of use 2026-05-26 CN claimed
WO-2026107113-A1 MODIFIED CELLS FOR PROGRAMMING EXTRA ENVELOPED VIRUSES (EEVs) AND THEIR USE FOR PRODUCING THE EEVs, THE PROGRAMMED EEVs AND USES THEREOF CALIDI BIOTHERAPEUTICS (NEVADA), INC. (US) 2026-05-21 WO claimed
US-12629363-B2 Prophylaxis and treatment of angioedema PHARVARIS GMBH (CH) 2026-05-19 US claimed
US-12631653-B2 Methods for diagnosing and treating uveitis THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2026-05-19 US claimed
CN-121668168-B Use of natural product in preparation of medicine for treating and/or preventing fungal diseases and composition thereof 昆明医科大学 2026-05-19 CN claimed
WO-2026102345-A1 METHODS OF ADMINISTERING THE VOLTAGE-GATED POTASSIUM CHANNEL OPENER AZETUKALNER XENON PHARMACEUTICALS INC. (CA) 2026-05-15 WO claimed
EP-4740962-A1 PHARMACEUTICAL COMPOSITION, FORMULATION CONTAINING PHARMACEUTICAL COMPOSITION, KIT CONTAINING PHARMACEUTICAL COMPOSITION, PREPARATION METHOD FOR PHARMACEUTICAL COMPOSITION, AND USE OF PHARMACEUTICAL COMPOSITION Shanghai WD Pharmaceutical Co., Ltd (CN) 2026-05-13 EP claimed
US-20260124224-A1 USE OF COMBINED COMPOSITION IN PREPARING DRUG FOR RESISTING FUNGAL AND BACTERIAL INFECTIONS NATIONAL CENTER FOR NANOSCIENCE AND TECHNOLOGY (CN) 2026-05-07 US claimed
EP-4255391-B1 LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION METRIOPHARM AG (CH) 2026-05-06 EP claimed
EP-0435436-A2 Transdermal flux enhancers in combination with iontophoresis in topical administration of pharmaceuticals PFIZER INC. (US) 1991-07-03 EP claimed
US-5023085-A Using 1-alkylazacycloheptan-2-one or substituted cis-olefin as dermal penetration enhancer PFIZER INC. (US) 1991-06-11 US claimed
EP-0430149-A2 Pharmaceutical preparations Heinrich Mack Nachf. (DE) 1991-06-05 EP claimed
US-4988697-A Alpha-demethylase inhibiting azole compound and a beta-lactone MERCK & CO., INC. (US) 1991-01-29 US claimed
WO-1990011754-A1 AEROSOLIZED AZOLE ANTIFUNGALS FISONS PLC (GB) 1990-10-18 WO claimed
EP-0367954-A1 Nikkomycin derivatives, antimycotic compositions of nikkomycin derivatives and azole antimycotics BAYER AG (DE) 1990-05-16 EP claimed
EP-0330923-A2 Nikkomycin derivatives, antimycotic compositions of nikkomycin derivatives and azole antimycotics BAYER AG (DE) 1989-09-06 EP claimed
EP-0310122-A1 Antifungal composition KAKEN PHARMACEUTICAL CO., LTD. (JP) 1989-04-05 EP claimed
EP-0178682-A2 1,3-Bis(1H-1,2,4-triazol-1-yl)-2-fluoro-2-(2,4-difluorophenyl)propane, antifungal composition containing it, and process for preparation of the compound and the composition SCHERING CORPORATION (US) 1986-04-23 EP claimed
US-4404216-A Antifungal 1,3-bis-triazolyl-2-propanol derivative PFIZER INC. (US) 1983-09-13 US claimed